Neal Franklin Fowler net worth and biography

Neal Fowler Biography and Net Worth

Director of Emergent Biosolutions

Neal is the Chief Executive Officer of Pathalys Pharma, Inc., a biomedicines company focused on chronic kidney disease. He previously served as CEO of Liquidia Technologies (NASDAQ), transforming the company from an early-stage research platform into a publicly traded biomedicines company. While at Liquidia, Neal also co-founded and served as CEO of Envisia Therapeutics (acquired), an ophthalmology company focused on therapeutics. Prior to Liquidia, Neal worked for seven years with Johnson and Johnson, serving as President of Centocor, Inc., a global multi-billion dollar subsidiary focused on biomedicines, and President of Ortho-McNeil Neurologics, a company focused on neurological disorders. Neal started his career with Eli Lilly and Company, working for thirteen years in a variety of sales, marketing and business development roles in both the pharmaceutical and medical device divisions.

Neal is the current chair of NCBIO and a past chair of the UNC Eshelman School of Pharmacy Foundation. He is a native of Raleigh, NC and earned his BS degree in Pharmacy and MBA, both from the University of North Carolina at Chapel Hill.

What is Neal Franklin Fowler's net worth?: The estimated net worth of Neal Franklin Fowler is at least $1.22 million as of March 12th, 2025. Fowler owns 101,100 shares of Emergent Biosolutions stock worth more than $1,217,547 as of December 5th. This net worth approximation does not reflect any other investments that Fowler may own. Learn More about Neal Franklin Fowler's net worth.
How do I contact Neal Franklin Fowler?: The corporate mailing address for Fowler and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Neal Franklin Fowler's contact information.
Has Neal Franklin Fowler been buying or selling shares of Emergent Biosolutions?: Neal Franklin Fowler has not been actively trading shares of Emergent Biosolutions within the last three months. Most recently, Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a transaction totalling $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares of the company's stock, valued at $589,413. Learn More on Neal Franklin Fowler's trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Neal Fowler (Director), Keith Katkin (Director), Richard Lindahl (CFO), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 88,382 shares worth more than $690,250.62. The most recent insider tranaction occured on October, 7th when EVP Coleen Glessner sold 30,608 shares worth more than $306,080.00. Insiders at Emergent Biosolutions own 1.2% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 10/7/2025.

Neal Franklin Fowler Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/12/2025	Sell	35,000	$5.83	$204,050.00	101,100

Neal Franklin Fowler Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $12.04

$11.52

$12.28

50 Day Range

MA: $10.09

$8.81

$12.78

2 Week Range

Now: $12.04

$4.02

$13.41

Volume

1,124,806 shs

Average Volume

827,770 shs

Market Capitalization

$632.50 million

P/E Ratio

9.26

Dividend Yield

N/A

Beta

2.32